Client Login | Refer a Friend | Search | Enroll Now | Free Info Kit

What is Cord Blood? What are Stem Cells? Diseases Treated Family Banking & Public Donation Real People, Real Stories Medical Testimonials Rights & Legislation Science & Research

Most Experienced Collection & Processing Corporate Stability Secure Facility Quality Service Research & Innovation One-Step Shipping Gift Registry Our Pricing Real People, Real Stories Families in Need

Cord Blood Stem Cells Banking Cord Blood Collecting Cord Blood Shipping and Handling Processing and Banking About CBR Enrolling With CBR Common Misconceptions

Cord Blood Banking Research Regenerative Medicine Research Brain Injury Juvenile Diabetes Heart Disease Cancer Corneal Regeneration

About Cord Blood Banking Why Cord Blood Registry? Principles in Action® Testimonials Common Misconceptions FAQs Request Materials Educational Programs Video Demonstration

Company Overview Newsroom CBR Newsletters Media Resources Career Opportunities Contact Us

About Us

Company Overview

Newsroom

Press Releases

Stem Cell News and Research

"The use of umbilical cord blood stem cells in the treatment of disease is one of the most prominent advancements in medicine today. Developments in this field will revolutionize medicine and disease treatment."

Roger Markwald M.D. Professor of Cell Biology, Medical University of South Carolina

Peripheral Vascular Disease; Autologous Bone Marrow Stem Cells Improve Chronic Limb Ischemia

March 16, 2006
Blood Weekly

2006 MAR 16 - (NewsRx.com) -- Autologous bone marrow stem cells improve chronic limb ischemia.

According to recent research from Germany, "A 62-year-old man had limb ischemia in stage IIb (Fontaine's classification). After surgical and interventional measures the right superficial femoral artery had remained occluded for more than 1 year."

"The patient's walking distance was only 100 meters. It was therefore decided to do a combined intra-arterial and intramuscular transplantation of stem cells into the right limb. Before and 10 weeks after the transplantation noninvasive tests, namely walking distance, ankle-brachial index at rest and during exercise, occlusion plethysmography and capillary venous oxygen saturation were measured," wrote T. Bartsch and colleagues, University of Dusseldorf.

"The patient was also asked to fill in a questionnaire of his symptoms. After harvesting the patient's bone marrow the mononuclear cell fraction was separated (109.8 X 106). Afterwards 10 ml of the cell suspension were injected into the right superficial femoral artery and 5 ml each of the suspension was injected into 5 different locations of the quadriceps femoris and the gastrocnemius muscles."

According to study data, "After 10 weeks' follow-up a 7-fold improvement of walking distance and an increase of tissue oxygen saturation of more then 50% were recorded. The ankle-brachial index at rest remained unchanged, but on exercise it increased by 24%."

"The combined intra-arterial and intramuscular transplantation of human autologous bone marrow stem cells may be a novel and clinically feasible treatment for patients with severe chronic limb ischemia. The success of this approach may be the result of increased neo-angiogenesis, especially of the small muscle-supplying vessels," researchers suggested.

Bartsch and colleagues published their study in Deutsche Medizinische Wochenschrift (Novel treatment of therapy-refractory limb ischemia by intra-arterial and intra-muscular transplantation of autologous adult bone marrow stem cells. Dtsch Med Wochenschr, 2006;131(3):79-83).

For additional information, contact B.E. Strauer, University of Dusseldorf, Klin Kardiol Pneumol & Angiology, Moorenstr 5, D-40225 Dusseldorf, Germany.

------------------------------------------------------------------------

View News & Media Disclaimer